Hyperthermia associated with 3,4‐methylenedioxyethamphetamine (‘Eve’)
B Tehan, R D Hardern, A. Bodenham
Anaesthesia June 1, 1993 DOI: 10.1111/j.1365-2044.1993.tb07072.x via OpenAlex
Summary
AI-generated from the abstractA patient with hyperthermia, muscle rigidity, rhabdomyolysis, and disseminated intravascular coagulation was initially suspected of taking MDMA (Ecstasy), but toxicology later revealed the presence of MDEA (Eve), a related drug. In vitro testing for malignant hyperthermia was negative.
Study at a glance
| Characteristics | Case study Case report Peer reviewed |
|---|---|
| Sample size | 1 |
| Population | A patient admitted with hyperthermia and related symptoms |
| Keywords | Medicine Malignant hyperthermia Anesthesia |
| Citations | 48 |
| Key finding | The patient's symptoms were associated with MDEA (Eve) rather than MDMA, and malignant hyperthermia was ruled out by in vitro testing. |
Abstract
Summary A patient was admitted with hyperthermia, muscle rigidity, rhabdomyolysis and disseminated intravascular coagulation. He was initially thought to have taken 3,4‐methylenedioxymethamphetamine (MDMA, ‘Ecstasy’), but subsequent toxicology revealed the presence of 3,4‐methylenedioxyethamphetamine (MDEA, ‘Eve’), its sister drug, in his blood. Subsequent in vitro testing for malignant hyperthermia proved to be negative.